

**Appendix Table 12. CLOSE-A** (randomization group 2: had contraindications to oral anticoagulants).

Variable	N	Full Sample	Device	Medication Therapy
<b>Recurrent ischemic strokes (primary outcome), events/N</b>		7/129	0/65	7/64
<b>Age in years, mean (sd)</b>	129	40.61 ( 11.18 )	39.59 ( 11.89)	41.65 ( 10.40)
<b>Male Gender</b>	129	84 (65.1%)	41 (63.1%)	43 (67.2%)
<b>White Race</b>	NR			
<b>Smoke</b>	129	36 (27.9%)	16 (24.6%)	20 (31.3%)
<b>Diabetes</b>	129	3 (2.3%)	1 (1.5%)	2 (3.1%)
<b>High Cholesterol</b>	129	22 (17.1%)	10 (15.4%)	12 (18.8%)
<b>Hypertension</b>	129	10 (7.8%)	5 (7.7%)	5 (7.8%)
<b>Prior Stroke</b>	129	4 (3.1%)	2 (3.1%)	2 (3.1%)
<b>Prior Stroke or TIA</b>	129	12 (9.3%)	5 (7.7%)	7 (10.9%)
<b>Atrial Septal Aneurysm</b>	129	53 (41.1%)	28 (43.1%)	25 (39.1%)
<b>Large Sized Shunt<sup>a</sup></b>	129	120 (93.0%)	60 (92.3%)	60 (93.8%)
<b>Presence of a Superficial Infarct<sup>b</sup></b>	129	85 (65.9%)	41 (63.1%)	44 (68.8%)
<b>Index Stroke (vs. TIA)</b>	129	129 (100%)	65 (100%)	64 (100%)

<sup>a</sup>>20 bubbles for all trials except CLOSURE (>25) and CLOSE (>30).

<sup>b</sup>Not reported in PC Trial.

NR, not reported; SD, standard deviation; TIA indicates transient ischemic attack.